Hired before the ICP was defined. Six months of outbound into the wrong market. The SDR was not the problem.
$24K–$60K
Wrong Agency
Executed perfectly against the wrong strategy. Deliverables arrived. Pipeline did not.
$120K–$180K
Wrong GTM Hire
VP Sales hired without a brief. First quarter spent figuring out what Wiremap would have answered in a week.
$100K+
Wrong Market
Expanded before the motion was validated. Different buyer, different urgency, different channel. Nothing transferred.
$499
The Wiremap
Understand what is actually limiting growth before you commit budget, people, or runway to a direction.
You run due diligence before you invest. Before you acquire. Before you sign. Run it before your next GTM decision too. The diagnosis costs less than a single day of a VP Sales hire — and tells you whether you are ready to make that hire at all.
Amulya Shankar
Founder, Wiremap
20+
Years in B2B SaaS GTM
15+
Startups taken to revenue
$25M+
Pipeline built
3×
Companies to $1M+ ARR
Why Wiremap exists
After reviewing hundreds of GTM plans, proposals, and growth strategies, one pattern appeared every time.
Founders were solving the wrong problem. Not because they lacked effort or intelligence. But because they committed to a direction before understanding what was actually wrong.
They hired before diagnosing. They executed before validating. They scaled before understanding. By the time the pattern was clear, months of runway had already been spent on the wrong problem.
The pattern that appeared — every time
Founder says: "Our SDR team isn't producing."
→
Reality: The ICP was too broad. The SDR was executing correctly against the wrong target.
Founder says: "Our messaging isn't landing."
→
Reality: The positioning was undifferentiated. Better copy into an unowned position still loses.
Founder says: "We need more leads."
→
Reality: They had a conversion problem, not a volume problem. More leads accelerated the leak.
"The moat is not domain expertise. A DevOps founder already understands DevOps better than we ever will. What they are paying for is commercial pattern recognition — the ability to translate what they know about their product into what is actually blocking revenue. That translation, turned into a repeatable structured system, is what Wiremap does."
Who this works for
Any B2B company where commercial complexity is the constraint — not technical complexity. The pattern recognition transfers across industries because the commercial questions are the same.
✓ B2B SaaS — all verticals
✓ Technology-enabled services
✓ AI and data products
✓ Cybersecurity and compliance
✓ FinTech and HR Tech
✓ B2B managed and professional services
Three products. Three decision stages.
What are you trying to decide?
Pick the product that matches where you are. Each one is built around the decision you are trying to make — not the deliverable you receive.
✦ Introductory pricing — prices are increasing shortly ✦
GTM Clarity Assessment
$499 current
Standard rate $799
GTM Risk Assessment
$999 current
Standard rate $1,499
Revenue Due Diligence
$2,499 current
Standard rate $3,999
⏳
Introductory pricing is available now. We deliberately launched at a price point that makes it easy to run the diagnosis before a major decision — because we believe founders should not have to spend $10,000 to find out what is actually blocking their growth. Standard rates are higher and will apply shortly. If current pricing is showing, it is still available.
Stage 1 · Pre-revenue to first traction
GTM Clarity Assessment
For founders asking: Am I pointing in the right direction before I spend more?
$499 introductory · standard rate $799
Decision this supports
"Should I keep building this motion, or is something fundamentally wrong before I go further?"
ICP assessment — who to actually target
Positioning analysis vs your 3 competitors
Messaging audit — what your copy signals to buyers
US and Canada. USD pricing via PayPal. Async delivery.
🇬🇧
United Kingdom
Strong focus on UK B2B SaaS and regulated sectors.
🌍
Europe
EU markets including DACH, Nordics, and Benelux.
🌏
Asia
India, Singapore, SEA. INR via Razorpay for India.
Everything after this — GTM framework design, advisory, implementation — is custom scoped after your due diligence is complete. No public pricing. No two situations are the same. Reach out after your report →
What the diagnosis actually finds
What the diagnosis actually finds
Real findings from real engagements. Company names withheld. The pattern of what gets discovered — consistently — across sectors and stages.
These are the findings. Each card links to the full report — scorecard, analysis, action plan, and maturity grid included.
What changed after the diagnosis
What changed after the diagnosis.
Early Stage · Compliance SaaS · London
Finding: ICP one layer too broad. Right industry, wrong buyer persona and no urgency trigger.
We had been running the same outbound for six months. Three weeks after applying the Wiremap findings, we booked 8 qualified meetings. That had never happened in a single month before.
Seed-Stage Founder
8 qualified meetings — month one
Growth Stage · Revenue Intelligence · New York
Finding: No repeatable motion. All pipeline from founder network. Investor question unanswerable.
Our investors kept asking about our repeatable GTM motion. We couldn't answer. The Wiremap gave us the answer and the evidence. The round closed six weeks after we implemented the findings.
Pre-Series A Founder
Round closed 6 weeks later
Growth Stage · Workflow SaaS · Bangalore → US
Finding: Sales hire brief undefined. VP would have rebuilt the motion from scratch in month one.
We were about to hire a Head of Sales. The Wiremap gave us the exact brief to hand them on day one. We probably saved six months of them figuring out what the report answered in a week.
Bootstrapped Founder
$72K+ in misdirected runway avoided
Company names withheld by request. Outcomes verified from delivered engagements.
Not a one-time report. A recurring practice.
Every major decision that touches your revenue engine deserves a diagnosis.
The founders who get the most from Wiremap do not buy once. They return every time something significant is about to change — before committing budget, headcount, or direction to a decision that cannot easily be undone.
👤
Before hiring or letting go of a sales or GTM person
Whether you are bringing someone in or recognising a mis-hire — run the diagnosis before the decision. Know what brief to give them or what gap you are actually trying to fill.
🛠️
Before implementing a new CRM, tool, or outbound system
Tools execute direction. Before you invest in new infrastructure, confirm the direction is correct. A CRM running the wrong motion at scale is more expensive than no CRM at all.
🌍
Before entering a new market or geography
The ICP, positioning, channel, and urgency trigger that worked in one market rarely transfers unchanged to the next. Validate before you commit headcount and budget to the assumption that it will.
🚀
When the product changes significantly
A new feature set, a new use case, a pivot driven by client feedback — each one can shift who your real buyer is. When the product changes, the GTM that was built around the old product may no longer fit.
📊
When client feedback is being built into the roadmap
Client feedback reveals what existing customers want. It does not always reveal what the next ICP cohort needs. Before reshaping product around feedback, confirm it is the right signal from the right buyers.
💰
Before raising or entering investor conversations
Investors will stress-test your GTM story. The diagnosis gives you the evidence to answer their questions — not founder narrative, but structured commercial intelligence built from your actual data.
📉
When pipeline stalls or conversion rates drop unexpectedly
A sudden drop in conversion is a signal, not a verdict. Before you change pricing, rebuild sequences, or fire the SDR — run the diagnosis. The problem is rarely where it appears to be.
🔄
When the motion stops working but nothing obvious changed
Markets shift. Competitors reposition. Buyer priorities evolve. A GTM motion that produced results six months ago can quietly stop working. Quarterly diagnosis catches drift before it becomes a crisis.
Early Stage founders
Run a diagnosis every time something meaningful changes.
At early stage, your GTM assumptions are still being tested. The ICP you started with is probably not the ICP that will scale. The channel that worked for the first 5 clients may not work for the next 50. Every significant shift in the business — new feature, new hire, new market signal — is a reason to re-diagnose before doubling down.
⟳ Every major decision · or every 90 days
Growth Stage founders
Make quarterly GTM diagnosis a standard operating practice.
At growth stage, the cost of running the wrong motion at scale is measured in hundreds of thousands of dollars. A quarterly Revenue Due Diligence is the difference between catching a drift early and discovering six months later that the ICP shifted, the messaging stopped landing, and the pipeline has been quietly degrading while the team stayed busy. The diagnosis is the board meeting your GTM motion never gets.
⟳ Quarterly · before every major GTM decision
"The founders who avoid expensive GTM mistakes are not luckier. They diagnose before they commit."
Wiremap is the practice you build around every decision that touches revenue.
The process
Four steps. No calls required.
Complete at your own pace. No calls required at any stage. Findings delivered to your portal when ready.
1
Pay and Access
Pay and receive your intake form link within 30 minutes. Specific to the product you chose.
30 minutes
2
Complete Intake
Fill in the intake form at your pace. 14 to 30 days to submit depending on product. Save and return anytime.
Your pace
3
Practitioner Review
Every submission is read before any analysis runs. Every finding validated against 20 years of pattern recognition.
7–10 business days
4
Findings Delivered
Your report arrives with a scored maturity grid, priority action plan, and the one thing to fix before anything else.
Delivered
Questions before you commit
Frequently asked
The short answer: less than you think. The intake form is structured to guide you through exactly what is needed. Nothing is assumed. Nothing requires perfect documentation. But knowing what to gather in advance makes the process faster. Here is what each product typically requires.
GTM Clarity Assessment — $499 · 14 days to submit
Suitable for founders who may not have formal documentation yet. You will need:
·A description of your product and the problem it solves — in your own words
·Your current ICP hypothesis — who you believe your buyer is, even if it is informal
·Your website URL and any outreach copy or sequences you have run
·A description of what you have tried so far — channels, campaigns, results
·Names of 2 to 3 competitors you know of
·Any customer or prospect feedback you have received — even informal
Who fills this in: the founder, or a co-founder. No other departments required. Most founders complete this in one sitting of 25 to 35 minutes.
GTM Risk Assessment — $999 · 14 days to submit
Requires more operational context. You will need everything from the GTM Clarity Assessment, plus:
·Your current ARR or MRR — even approximate
·A summary of your sales motion — outbound, inbound, referral, or a mix
·Your current tech stack — what tools you are using for outreach, CRM, and tracking
·Outbound metrics if available — emails sent, reply rates, meetings booked, close rates
·A description of the decision you are trying to make — the hire, the agency, the market
·What is currently blocking growth in your view — even if you are unsure whether you are right
Who fills this in: the founder plus, if relevant, your Head of Sales or SDR lead for the operational metrics. Allow 35 to 50 minutes across one or two sessions.
Revenue Due Diligence — $2,499 · 30 days to submit
The most comprehensive intake. Requires data from multiple parts of the business. You will need everything from the GTM Risk Assessment, plus:
·A pipeline export or summary from your CRM — open deals, stages, close rates, deal sizes
·Closed-won data — which segments, titles, and company sizes have actually bought
·Closed-lost data — where deals stall, what objections appear, which stages lose the most
·Your current team structure — who owns what in sales, marketing, and GTM
·Marketing performance if applicable — MQLs, conversion rates, channel breakdown
·Any investor or board questions about GTM you are currently unable to answer cleanly
·Your fundraising timeline and current investor conversation status if raising
Who fills this in: the founder with input from Head of Sales, Revenue Operations or whoever manages your CRM, and optionally your CFO or finance lead for revenue data. The 30-day window exists precisely because this data often needs to be pulled from multiple sources. You do not need everything on day one — start with what you have and gather the rest within your window.
If you are unsure whether you have enough information to complete the intake — start anyway. Partial information still produces useful findings. We will flag where additional data would strengthen the diagnosis and you can add it before you submit.
The due diligence you've been skipping
Before you hire, scale, raise, or expand — run due diligence on your revenue engine.
Understand what is actually limiting growth before you commit to a direction. The diagnosis costs less than a single wrong decision.
